Research & Development



第一三九章 天子薄情   何愁有呵呵笑道︰“看來真把你逼急了,算了,不願意說就不說,不用糊弄我。”下载app送20的彩票   雲瑯推開曹襄騷擾他睡覺的手煩躁的道︰“沒了就沒了,這里葡萄很多,我們繼續釀造一些就是了。”手机投注彩票app下载   雲瑯說完,張安世雙膝跪倒拜謝道︰“叔父所言,安世感激不盡,他日但有所成,皆拜叔父所賜。”   到時候啊,關中熟,天下足,並非難事,如果成就這樣的事情,天下還有誰能撼動我大漢江山基業?彩票app最新版下载   那些平日里跟他非常不對付的勛貴,此刻沒了趾高氣揚的模樣,不敢與張湯對視!

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo